Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 11, 2008

View Archived Issues

Inhibition of ErbB3 receptor by EZN-3920 shows antitumor activity in preclinical studies

MTD established in a phase I advanced cancer study of oral c-Met inhibitor ARQ-197

Novel class of antibacterial pyrrolamides targeting DNA gyrase identified

ARRY-162 safe, affects biomarkers in phase I studies

Increased exposure seen with deuterated linezolid compared with linezolid in vivo

Allergan reviews Q3 accomplishments

ArQule and Daiichi Sankyo enter strategic R&D cancer program

Azur and Elan sign agreement to develop once-daily clozapine

EntreMed meets primary efficacy endpoint in phase I/II NSCLC trial

ProtoKinetix receives independent confirmation of AAGP antiinflammatory action

FDA clears Celgene's placenta-derived stem cells for first clinical study

FDA and DOR agree on design of phase III study of orBec in GI GVHD

Dosing is initiated in INFORM-1 clinical trial of R-7227 and R-7128 for HCV

Aradigm announces results from clinical trial of inhaled treprostinil with AERx inhaler

Amgen provides pipeline update at recent investors meeting

GSK and XenoPort plan to withdraw and resubmit Solzira NDA for RLS

Xoma restructures drug development collaboration with Novartis

Insmed gains royalty-free worldwide rights for Iplex for ALS

TorreyPines sells AD genetics program to Eisai, enabling advancement of clinical-stage assets

Optimer presents data from North American phase III OPT-80 study

Recent patents disclose novel therapeutic agents for asthma and other indications

New treatment options for urological disorders reported in recent patents

Novel agents for psychiatric disorders described in recent patent literature

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...